Griseofulvin, a novel host-directed antimalarial drug [ 2013 - 2016 ]

Research Grant

Researchers: Prof Simon Foote (Principal investigator) ,  A/Pr Brendan Mcmorran ,  The Australian National University (Managed by)

Brief description This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.

Funding Amount $AUD 461,551.50

Funding Scheme Project Grants

Notes Standard Project Grant